BR112022016405A2 - Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento - Google Patents

Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento

Info

Publication number
BR112022016405A2
BR112022016405A2 BR112022016405A BR112022016405A BR112022016405A2 BR 112022016405 A2 BR112022016405 A2 BR 112022016405A2 BR 112022016405 A BR112022016405 A BR 112022016405A BR 112022016405 A BR112022016405 A BR 112022016405A BR 112022016405 A2 BR112022016405 A2 BR 112022016405A2
Authority
BR
Brazil
Prior art keywords
voxelotor
treatment
pharmaceutical composition
crystalline form
crystalline forms
Prior art date
Application number
BR112022016405A
Other languages
English (en)
Inventor
Bonnaud Thierry
Prentice Zoe
Original Assignee
Macfarlan Smith Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlan Smith Ltd filed Critical Macfarlan Smith Ltd
Publication of BR112022016405A2 publication Critical patent/BR112022016405A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMA CRISTALINA DE VOXELOTOR, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAMENTO, E, VOXELOTOR PARA USO NO TRATAMENTO. A presente invenção se refere às formas cristalinas de voxelotor, aos processos para a preparação deles, e às composições farmacêuticas contendo as formas cristalinas.
BR112022016405A 2020-02-24 2021-02-17 Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento BR112022016405A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2002560.7A GB202002560D0 (en) 2020-02-24 2020-02-24 Crystalline forms of voxelotor, and processes for the preparation thereof
PCT/GB2021/050380 WO2021170977A1 (en) 2020-02-24 2021-02-17 Crystalline forms of voxelotor, and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
BR112022016405A2 true BR112022016405A2 (pt) 2023-01-10

Family

ID=70108361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016405A BR112022016405A2 (pt) 2020-02-24 2021-02-17 Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento

Country Status (9)

Country Link
US (1) US20230126277A1 (pt)
EP (1) EP4110770A1 (pt)
JP (1) JP2023520619A (pt)
KR (1) KR20230015306A (pt)
CN (1) CN115768759A (pt)
BR (1) BR112022016405A2 (pt)
CA (1) CA3165764A1 (pt)
GB (1) GB202002560D0 (pt)
WO (1) WO2021170977A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023199345A1 (en) * 2022-04-14 2023-10-19 Msn Laboratories Private Limited, R&D Center Novel solid state forms of voxelotor and their preparation methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201403645VA (en) 2011-12-28 2014-07-30 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2015031285A1 (en) * 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
AP2016009261A0 (en) * 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) * 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
TWI825524B (zh) * 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法

Also Published As

Publication number Publication date
WO2021170977A1 (en) 2021-09-02
KR20230015306A (ko) 2023-01-31
CN115768759A (zh) 2023-03-07
JP2023520619A (ja) 2023-05-18
GB202002560D0 (en) 2020-04-08
CA3165764A1 (en) 2021-09-02
EP4110770A1 (en) 2023-01-04
US20230126277A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
ECSP14004812A (es) Triazolopiridinas sustituidas
CL2013002185A1 (es) Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
GT201300254A (es) Triazolopiridinas
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
CR20160433A (es) Nuevos compuestos
BR112017013498B8 (pt) Formulação agrícola, seu método de preparação, e composição agrícola aquosa
EA202090448A1 (ru) Дигидрооксадиазиноны
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
CR20160016A (es) Pirazolpiridinas sustituidas
BR112022016405A2 (pt) Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento
BR112015031820A2 (pt) composto, composição farmacêutica, intermediário, processo para a preparação de um composto e métodos
CL2018003739A1 (es) Formas cristalinas de un compuesto de tetraciclina sustituida con 9-aminometilo y un método para su preparación.
BR112022000229A2 (pt) Composição para uso no tratamento da perda de cabelo
BR112021019437A2 (pt) Composições de biofilme probiótico e métodos para preparar as mesmas
BR112019000603A2 (pt) composto, composição farmacêutica, método para o tratamento de doenças e uso do composto
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol
UY34630A (es) Imidazopiridazinas sustituidas con amino

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]